Sanofi Seeks Independence For API Unit Despite Stormy Market

IPO Plans Shelved In Favor Of Spin-Off

The French drugmaker is pushing ahead with a listing of its Euroapi business on the Euronext in the next couple of months, in spite of the turbulence that the Russian invasion of Ukraine has brought to stock markets.

Vertolaye
Workers at the Vertolaye site • Source: Euroapi

A couple of years after spinning out its active pharmaceutical ingredient (API) manufacturing business, Sanofi is now ready to list the standalone unit, called Euroapi, despite highly volatile market conditions.

In February 2020, the company set out its ambition to create a powerhouse API company by pooling the activities of six of its production sites: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Business